Last mentioned: Mar 9, 2026
$85M Private Placement
Company announces oversubscribed funding to accelerate clinical trials.
Platform Validation
Preclinical data for lead AATD program shows high editing efficiency.
Merger Completion
Korro Bio becomes a public entity via merger with Freeline Therapeutics.
Korro Bio has announced an oversubscribed $85 million private placement, signaling strong investor confidence in its proprietary RNA editing platform. This capital injection is expected to extend the company's cash runway and accelerate the clinical development of its lead programs targeting genetic diseases.
This page surfaces every story mentioning OPERA Platform across our startup coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running startup beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where OPERA Platform was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |